A recent edition of the JAMA Ophthalmology medical journal presented two EzriCare Artificial Tears case reports about serious infection and vision loss associated with these over-the-counter (OTC) eye drops from Global Pharma.
The two EzriCare Artificial Tears case reports are set forth in these March 2023 JAMA Ophthalmology medical journal articles:
- “Pseudomonas aeruginosa Corneal Ulcer Associated With Artificial Tears Eye Drops”
- “Multidrug-Resistant Pseudomonas aeruginosa Keratitis Associated With Artificial Tear Use”
This March 22, 2023, MedPage Today news item, “Case Reports Detail Vision Loss Linked to Recalled Artificial Tears”, points out these observations found in the March 2023 JAMA Ophthalmology medical journal edition with the articles about these serious eye infections due to the use of EzriCare Artificial Tears eye drops:
The current outbreak of MDR P. aeruginosa “associated with the use of carboxymethylcellulose sodium (EzriCare) multidose preservative-free artificial tears may be a wake-up call for the field,” the editorialists wrote, and “is a harsh reminder that all eye drops, including artificial tears, are medications with potential adverse effects, most commonly ocular but potentially systemic.”…
We have been following EzriCare Artificial Tears case reports since early February 2023, when the FDA issued its first warning about Global Pharma eye products. Since then, this drug safety issue has expanded to include:
- Delsam Pharma’s Artificial Eye Ointment;
- Delsam Pharma’s Artificial Tears; and,
- EzriCare Artificial Tears.
Let us know if we can be of assistance to you or someone you know by submitting an online Case Evaluation Form or calling us at 800-426-9535.[Read article in full at original source]
EzriCare Artificial Tears
Delsam Pharma’s Artificial Tears
Free Case Evaluation
Strictly Confidential, No Obligation